CTRI/2020/03/024089尚未招募未知
A Randomised controlled parallel group clinical study to evaluate Kushtanashana rasa and panchatiktha ghritha guggulu with Kutaja patra suryapaki taila external application in the management of Eka Kushta w.s.r to Psoriasis
Dr Supreetha M0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.With classical signs and symptoms of Eka Kushta.
- •2. Presenting with signs and symptoms of Psoriasis.
- •3. The Subjects willing to give informed consent for research.
排除标准
- •1.Subjects aged <21 years and > 60 years of age .
- •2.Subjects suffering from complications of Psoriasis like Psoriatic arthritis .
- •3.Subjects suffering from Nonâ??psoriatic conditions of skin, IHD, Immune compromised patients and other uncontrolled systemic diseases.
- •4.Disease which interferes with the course of disease and treatment.
- •5.Pregnant and Lactating women.
研究者
相似试验
尚未招募
不适用
se of Kanchanar Triphaladi Yog along with Thyroxine in HypothyroidismCTRI/2022/07/044382Dr Himani
招募中
1 期
A clinical trial to study the effect of two dosage forms of a herb(Leonotis nepetifolia)in patients with OsteoarthritisCTRI/2013/03/003465il40
已完成
3 期
Determining the effectiveness, safety and tolerability of Actoverco Filgrastim and Actoverco Pegfilgrastim compared to Neupogen in preventing the chemotherapy induced neutopenia in treatment of the breast cancerbreast cancer.breast cancerIRCT2013042212398N4Actoverco Pharmaceutic Company156
招募中
Unknown
A Randomized, Double-Blind, Parallel Group Clinical Study To Evaluate Efficacy And Safety Of UO ABG 01 In The Management Of Borderline Cardio Vascular Risk FactorsCTRI/2023/10/058501Xtractiva Life Science Private Limited
进行中（未招募）
1 期
A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55mg/kg, 2.5mg/kg or 10mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years - Mepolizumab in paediatric eosinophilic oesophagitisEosinophilic oesophagitisEUCTR2005-006074-10-GBGlaxoSmithKline Research & Development Ltd.72